valproic acid has been researched along with Retinitis Pigmentosa in 16 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Retinitis Pigmentosa: Hereditary, progressive degeneration of the retina due to death of ROD PHOTORECEPTORS initially and subsequent death of CONE PHOTORECEPTORS. It is characterized by deposition of pigment in the retina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa." | 9.27 | Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. ( Bernstein, PS; Birch, DG; Bramer, S; Chegarnov, E; Csaky, K; Erker, L; Fish, GE; Francis, PJ; Hartnett, ME; Heckenlively, J; Hughbanks-Wheaton, DK; Iannacone, A; Jayasundera, T; Lam, BL; Lindblad, R; McCormack, J; Pennesi, ME; Rose, S; Sklaver, NL; Smith, T; Teske, MP; VanVeldhuisen, PC; Wahle, A; Warner, J; Weleber, RG; Winthrop, KL; Yang, P; Zilliox, P, 2018) |
| "To evaluate the efficacy of valproic acid (VPA) on visual function in patients with retinitis pigmentosa (RP)." | 9.19 | Efficacy of oral valproic acid in patients with retinitis pigmentosa. ( Chohan, A; Gogia, V; Gupta, S; Kumar, A; Midha, N; Sehra, S, 2014) |
| "To evaluate the efficacy and safety of valproic acid (VPA) treatment in patients with retinitis pigmentosa (RP)." | 7.85 | The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa. ( Dervişogulları, MS; Güler, E; Totan, Y; Yüce, A, 2017) |
| "To examine the efficacy and safety of valproic acid (VPA) in patients with retinitis pigmentosa (RP)." | 7.77 | Therapeutic potential of valproic acid for retinitis pigmentosa. ( Bigelow, C; Checchi, JM; Clemson, CM; Kaushal, S; Krebs, M; Tzekov, R, 2011) |
| "VPA plays a complex role in patients with pigmentary retinal dystrophies and may be associated with VA and field decline as well as adverse side effects." | 5.39 | Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. ( Bhalla, S; Bhullar, S; Joshi, D; Kasuga, D; Kay, CN; Park, Y, 2013) |
| "To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa." | 5.27 | Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. ( Bernstein, PS; Birch, DG; Bramer, S; Chegarnov, E; Csaky, K; Erker, L; Fish, GE; Francis, PJ; Hartnett, ME; Heckenlively, J; Hughbanks-Wheaton, DK; Iannacone, A; Jayasundera, T; Lam, BL; Lindblad, R; McCormack, J; Pennesi, ME; Rose, S; Sklaver, NL; Smith, T; Teske, MP; VanVeldhuisen, PC; Wahle, A; Warner, J; Weleber, RG; Winthrop, KL; Yang, P; Zilliox, P, 2018) |
| "Data for this observational case study were collected at the Department of Ophthalmology, University of California, Los Angeles, from May 1 to July 30, 2015, and included SD-OCT images of a subset of patients from the Trial of Oral Valproic Acid for Retinitis Pigmentosa." | 5.22 | Quantification of Ellipsoid Zone Changes in Retinitis Pigmentosa Using en Face Spectral Domain-Optical Coherence Tomography. ( Birch, DG; Ferris, FL; Francis, P; Hariri, AH; Ho, A; Sadda, SR; Weleber, RG; Zhang, HY, 2016) |
| "To evaluate the efficacy of valproic acid (VPA) on visual function in patients with retinitis pigmentosa (RP)." | 5.19 | Efficacy of oral valproic acid in patients with retinitis pigmentosa. ( Chohan, A; Gogia, V; Gupta, S; Kumar, A; Midha, N; Sehra, S, 2014) |
| "To evaluate the efficacy and safety of valproic acid (VPA) treatment in patients with retinitis pigmentosa (RP)." | 3.85 | The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa. ( Dervişogulları, MS; Güler, E; Totan, Y; Yüce, A, 2017) |
| "To examine the efficacy and safety of valproic acid (VPA) in patients with retinitis pigmentosa (RP)." | 3.77 | Therapeutic potential of valproic acid for retinitis pigmentosa. ( Bigelow, C; Checchi, JM; Clemson, CM; Kaushal, S; Krebs, M; Tzekov, R, 2011) |
| "VPA plays a complex role in patients with pigmentary retinal dystrophies and may be associated with VA and field decline as well as adverse side effects." | 1.39 | Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. ( Bhalla, S; Bhullar, S; Joshi, D; Kasuga, D; Kay, CN; Park, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (93.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Razzaghi, N | 1 |
| Fernandez-Gonzalez, P | 1 |
| Mas-Sanchez, A | 1 |
| Vila-Julià, G | 1 |
| Perez, JJ | 1 |
| Garriga, P | 1 |
| Vent-Schmidt, RYJ | 1 |
| Wen, RH | 1 |
| Zong, Z | 1 |
| Chiu, CN | 1 |
| Tam, BM | 1 |
| May, CG | 1 |
| Moritz, OL | 1 |
| Todd, L | 1 |
| Zelinka, C | 1 |
| Totan, Y | 1 |
| Güler, E | 1 |
| Yüce, A | 1 |
| Dervişogulları, MS | 1 |
| Huang, XF | 1 |
| Birch, DG | 2 |
| Bernstein, PS | 1 |
| Iannacone, A | 1 |
| Pennesi, ME | 1 |
| Lam, BL | 1 |
| Heckenlively, J | 1 |
| Csaky, K | 1 |
| Hartnett, ME | 1 |
| Winthrop, KL | 1 |
| Jayasundera, T | 1 |
| Hughbanks-Wheaton, DK | 1 |
| Warner, J | 1 |
| Yang, P | 1 |
| Fish, GE | 1 |
| Teske, MP | 1 |
| Sklaver, NL | 1 |
| Erker, L | 1 |
| Chegarnov, E | 1 |
| Smith, T | 1 |
| Wahle, A | 1 |
| VanVeldhuisen, PC | 1 |
| McCormack, J | 1 |
| Lindblad, R | 1 |
| Bramer, S | 1 |
| Rose, S | 2 |
| Zilliox, P | 2 |
| Francis, PJ | 2 |
| Weleber, RG | 2 |
| Brooks, BP | 1 |
| Jeffrey, B | 1 |
| Bhalla, S | 1 |
| Joshi, D | 1 |
| Bhullar, S | 1 |
| Kasuga, D | 1 |
| Park, Y | 1 |
| Kay, CN | 1 |
| Kumar, A | 1 |
| Midha, N | 1 |
| Gogia, V | 1 |
| Gupta, S | 1 |
| Sehra, S | 1 |
| Chohan, A | 1 |
| Hariri, AH | 1 |
| Zhang, HY | 1 |
| Ho, A | 1 |
| Francis, P | 1 |
| Ferris, FL | 1 |
| Sadda, SR | 1 |
| Clemson, CM | 1 |
| Tzekov, R | 2 |
| Krebs, M | 2 |
| Checchi, JM | 1 |
| Bigelow, C | 2 |
| Kaushal, S | 2 |
| van Schooneveld, MJ | 1 |
| van den Born, LI | 1 |
| van Genderen, M | 1 |
| Bollemeijer, JG | 1 |
| Sandberg, MA | 1 |
| Rosner, B | 1 |
| Weigel-DiFranco, C | 1 |
| Berson, EL | 1 |
| Clemson, C | 1 |
| Checchi, J | 1 |
| Sisk, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa[NCT05537220] | Phase 3 | 438 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
1 review available for valproic acid and Retinitis Pigmentosa
| Article | Year |
|---|---|
Current Pharmacological Concepts in the Treatment of the Retinitis Pigmentosa.
Topics: Animals; Clinical Trials as Topic; Docosahexaenoic Acids; Drug Discovery; Drug Evaluation, Preclinic | 2018 |
3 trials available for valproic acid and Retinitis Pigmentosa
| Article | Year |
|---|---|
Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Double-Blind Method; Electroretinography; Female | 2018 |
Efficacy of oral valproic acid in patients with retinitis pigmentosa.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Female; Humans; Male; Middle Aged; Pilot Pr | 2014 |
Quantification of Ellipsoid Zone Changes in Retinitis Pigmentosa Using en Face Spectral Domain-Optical Coherence Tomography.
Topics: Aged; Electroretinography; Female; GABA Agents; Humans; Male; Middle Aged; Observer Variation; Repro | 2016 |
12 other studies available for valproic acid and Retinitis Pigmentosa
| Article | Year |
|---|---|
Effect of Sodium Valproate on the Conformational Stability of the Visual G Protein-Coupled Receptor Rhodopsin.
Topics: Animals; Humans; Mutation; Protein Conformation; Receptors, G-Protein-Coupled; Retinitis Pigmentosa; | 2021 |
Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic
Topics: Animals; Autophagosomes; Histone Deacetylase Inhibitors; Histones; Humans; Photoreceptor Cells; Reti | 2017 |
Valproic Acid for a Treatment of Retinitis Pigmentosa: Reasons for Optimism and Caution.
Topics: Animals; Animals, Genetically Modified; Histone Deacetylase Inhibitors; Retinitis Pigmentosa; Valpro | 2017 |
The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Electroretinography; Enzyme Inhibitors; Female; | 2017 |
Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa: Lessons Learned From a Trial of Valproic Acid.
Topics: Blindness; Humans; Randomized Controlled Trials as Topic; Retinitis Pigmentosa; Valproic Acid; Visio | 2018 |
Errors in Potential Conflicts of Interest Disclosures, Author Affiliation, and Role of Funder.
Topics: Blindness; Conflict of Interest; Disclosure; Humans; Retinitis Pigmentosa; Valproic Acid | 2018 |
Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid.
Topics: Adolescent; Adult; Follow-Up Studies; GABA Agents; Humans; Liver Function Tests; Middle Aged; Retina | 2013 |
Therapeutic potential of valproic acid for retinitis pigmentosa.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Pilot Projects; Retinitis Pigmentosa; Retrospe | 2011 |
The conclusions of Clemson et al concerning valproic acid are premature.
Topics: Humans; Retinitis Pigmentosa; Valproic Acid; Visual Acuity | 2011 |
Lack of scientific rationale for use of valproic acid for retinitis pigmentosa.
Topics: Humans; Retinitis Pigmentosa; Treatment Outcome; Valproic Acid; Visual Acuity | 2011 |
Authors’ response.
Topics: Humans; Retinitis Pigmentosa; Valproic Acid; Visual Acuity | 2011 |
Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa.
Topics: Female; Humans; Male; Retinitis Pigmentosa; Valproic Acid | 2012 |